Scarica l'app Stockscreener
2.9691
1.37%
-0.0591
Precedente Chiudi:
$2.91
Aprire:
$2.99
Volume 24 ore:
1,180
Relative Volume:
0.03
Capitalizzazione di mercato:
$118.92M
Reddito:
$24.38M
Utile/perdita netta:
$-53.95M
Rapporto P/E:
-1.2021
EPS:
-2.47
Flusso di cassa netto:
$-23.31M
1 W Prestazione:
+8.71%
1M Prestazione:
-3.04%
6M Prestazione:
-24.27%
1 anno Prestazione:
-7.12%
Intervallo 1D:
$2.7401
$2.99
Intervallo di 1 settimana:
$2.4721
$2.99
Portata 52W:
$2.28
$5.24
Elutia Inc Stock (ELUT) Company Profile
Nome
Elutia Inc
Settore
Industria
Telefono
240-247-1143
Indirizzo
12510 PROSPERITY DRIVE, SILVER SPRING
Confronta ELUT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
2.7401 | 118.92M | 24.38M | -53.95M | -23.31M | -2.47 |
|
ABT
Abbott Laboratories
|
129.54 | 228.29B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
93.77 | 145.69B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
358.40 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
85.46 | 112.70B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.30 | 42.75B | 5.72B | 4.17B | 259.90M | 6.97 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-11-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-02 | Iniziato | Cowen | Outperform |
| 2020-11-02 | Iniziato | Piper Sandler | Overweight |
| 2020-11-02 | Iniziato | Truist | Buy |
Elutia Inc Borsa (ELUT) Ultime notizie
EluPro™ Named as 2025 Edison Award Winner - The Manila Times
Elutia to Participate in Upcoming Investor Conferences - TradingView
Exclusive Investor Access: Elutia CEO to Showcase Drug-Eluting Innovation at Premier Conferences - Stock Titan
AIGH Capital Management LLC Has $11.50 Million Position in Elutia Inc. (NASDAQ:ELUT) - MarketBeat
Elutia to Debut EluPro™ at HRS 2025Experience the Difference Biology Makes - The Manila Times
Revolutionary Biological CIED Protection: Elutia Unveils Dual-Antibiotic EluPro Technology - Stock Titan
Elutia Inc. reports mixed preliminary 2024 financial results - MSN
Elutia Inc. secures deal with Advantus Health Partners By Investing.com - Investing.com South Africa
Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro?? - MarketScreener
Elutia Enters GPO Deal With Advantus Health Partners - MarketScreener
Elutia Inc. secures deal with Advantus Health Partners - Investing.com
Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™ - The Manila Times
Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro - TradingView
Healthcare Milestone: Elutia Secures 7th GPO Deal for Revolutionary Antibiotic Device - Stock Titan
Elutia publishes new preclinical data in Antibiotics - TipRanks
Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope - The Manila Times
Groundbreaking Clinical Data: Elutia's FDA-Cleared Device Eliminates All Tested Bacteria - Stock Titan
Elutia Files For Mixed Shelf Of Up To $100 MillionSEC Filing -March 18, 2025 at 06:23 am EDT - Marketscreener.com
Elutia stock soars, Anteris falls in medical devices sector By Investing.com - Investing.com South Africa
Elutia stock soars, Anteris falls in medical devices sector - Investing.com India
HighCape Capital buys $1.05 million in Elutia Inc. stock By Investing.com - Investing.com South Africa
HighCape Capital buys $1.05 million in Elutia Inc. stock - Investing.com India
Elutia Inc. sees $1.05 million stock purchase by HighCape entities - Investing.com Australia
Elutia Inc. Reports Strong Demand for EluPro™ - TipRanks
ELUTIA INC. SEC 10-K Report - TradingView
Earnings call transcript: Elutia Q4 2024 misses forecasts, stock drops By Investing.com - Investing.com Australia
Elutia’s (ELUT) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
Earnings call transcript: Elutia Q4 2024 misses forecasts, stock drops - Investing.com India
Elutia Inc (ELUT) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Product Growth ... - Yahoo Finance
Elutia Inc (ELUT) Q4 2024 Earnings Call Highlights: Strategic Pa - GuruFocus.com
Elutia Inc (ELUT) Reports Q4 2024 Earnings: EPS of -$0.25 Meets - GuruFocus.com
Elutia reports Q4 EPS (26c) vs. (40c) last year - TipRanks
Elutia Inc. Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out - The Manila Times
Can Elutia's EluPro Success Overcome Broader Revenue Challenges? Q4 Earnings Deep Dive - StockTitan
Earnings To Watch: Elutia Inc (ELUT) Reports Q4 2024 Result - GuruFocus.com
Elutia Inc. (NASDAQ:ELUT) Short Interest Update - Defense World
Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025 - The Manila Times
Can This Drug-Eluting Biomatrix Leader Maintain Its Innovation Momentum? Q4 Results Coming - Stock Titan
Elutia Inc. secures $15 million through stock and warrant sale By Investing.com - Investing.com Nigeria
Elutia’s $15 Million Registered Direct Offering - Global Legal Chronicle
Private equity firms are Elutia Inc.'s (NASDAQ:ELUT) biggest owners and were hit after market cap dropped US$3.9m - Yahoo Finance
Elutia (NASDAQ: ELUT) Preparing to Release 2024 Financial Results - Defense World
Aziyo Biologics Announces Strategic Financial Offering - TipRanks
Elutia Inc. (NASDAQ:ELUT) Short Interest Up 29.8% in January - MarketBeat
Elutia Inc. secures $15 million through stock and warrant sale - Investing.com India
Elutia Inc. reports mixed preliminary 2024 financial results By Investing.com - Investing.com Australia
Elutia Inc Azioni (ELUT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Elutia Inc Azioni (ELUT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| HighCape Capital, L.P. | Director |
Feb 03 '25 |
Buy |
2.50 |
420,000 |
1,050,000 |
9,520,232 |
| Ferguson Matthew | CHIEF FINANCIAL OFFICER |
Jul 31 '24 |
Option Exercise |
1.43 |
105,080 |
150,002 |
257,823 |
4.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):